X4 Pharmaceuticals Inc (NASDAQ:XFOR) — Market Cap & Net Worth
Market Cap & Net Worth: X4 Pharmaceuticals Inc (XFOR)
X4 Pharmaceuticals Inc (NASDAQ:XFOR) has a market capitalization of $348.01 Million ($348.01 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14199 globally and #3391 in its home market, demonstrating a 0.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying X4 Pharmaceuticals Inc's stock price $3.51 by its total outstanding shares 99146743 (99.15 Million). Also see XFOR total assets for a full breakdown of the balance sheet.
X4 Pharmaceuticals Inc Market Cap History: 2017 to 2026
X4 Pharmaceuticals Inc's market capitalization history from 2017 to 2026. Data shows change from $7.59 Billion to $348.01 Million (-30.20% CAGR). Also see X4 Pharmaceuticals Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
X4 Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #386 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1384 of 3165 |
Weight: X4 Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
X4 Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how X4 Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check X4 Pharmaceuticals Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
11.29x
X4 Pharmaceuticals Inc's market cap is 11.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.38 Billion | $3.50 Million | -$33.28 Million | 394.32x | N/A |
| 2019 | $1.06 Billion | $3.00 Million | -$52.81 Million | 353.62x | N/A |
| 2020 | $637.51 Million | $3.00 Million | -$62.13 Million | 212.50x | N/A |
| 2024 | $72.73 Million | $2.56 Million | -$37.45 Million | 28.45x | N/A |
| 2025 | $396.59 Million | $35.11 Million | -$79.20 Million | 11.29x | N/A |
Competitor Companies of XFOR by Market Capitalization
Companies near X4 Pharmaceuticals Inc in the global market cap rankings as of September 18, 2026. Review XFOR goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to X4 Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
X4 Pharmaceuticals Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, X4 Pharmaceuticals Inc's market cap moved from $7.59 Billion to $ 348.01 Million, with a yearly change of -30.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $348.01 Million | -12.25% |
| 2025 | $396.59 Million | +445.26% |
| 2024 | $72.73 Million | -12.56% |
| 2023 | $83.18 Million | -15.51% |
| 2022 | $98.45 Million | -56.64% |
| 2021 | $227.05 Million | -64.39% |
| 2020 | $637.51 Million | -39.91% |
| 2019 | $1.06 Billion | -23.13% |
| 2018 | $1.38 Billion | -81.82% |
| 2017 | $7.59 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of X4 Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $348.01 Million USD |
| MoneyControl | $348.01 Million USD |
| MarketWatch | $348.01 Million USD |
| marketcap.company | $348.01 Million USD |
| Reuters | $348.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections… Read more